While new market expansion and acquisitions are expected to play out well, differing revenue structures and supply/demand concerns could have an unfavorable effect on earnings. Here’s what to watch for this week from Aeterna Zentaris Inc. (USA) (NASDAQ:AEZS), Micron Technology, Inc. (NASDAQ:MU), and BlackBerry Ltd (NASDAQ:BBRY).

Aeterna Zentaris Inc. (USA)

Aeterna Zenaris will release earnings on Tuesday, March 29 after market close. For the fourth quarter, analysts are expecting revenues of $450,000 and a loss of ($1.30) per share, compared to revenues of $11,000 and earnings of $0.06 per share from the same quarter of last year.

Analysts will be watching for any updates regarding Zoptrext, the company’s lead product currently in phase 3 testing for women with advanced metastatic endometrial cancer. The study should be completed by 3Q16 and depending on the results, the company could file an NDA and MAA with the FDA in 2017. In the fourth quarter, the company expressed interest in developing the drug in international markets. CEO David Dodd stated, “We continue discussions with others about adding to our portfolio of promoted products and about the commercial rights to and development of Zoptrex™ in markets outside the United States.”

Analysts will also be watching for updates on the company’s prostate cancer test APIFINY, co-promoted with Armune BioSciences. Aeterna Zenaris will earn commissions based on the number of tests performed in the U.S., however analysts believe the uptake may be slow. Following this announcement in early December, analyst Neil Maruoka of Canaccord Genuity weighed in on the company with a Speculative Buy rating and $13 price target on December 2, 2015. He stated, “We believe APIFINY is a nice incremental addition to

to Aeterna‘s portfolio, and should be complementary to Zoptrex (currently in a Phase III study in endometrial cancer) by providing the company’s existing sales force with exposure to the oncology market.” The analyst continued, Aeterna Zentaris estimates >200,000 new cases of prostate cancer in the US during 2015. This market is a decent size; however, with ~2,500 orders of APIFINY during its first 8 months, we expect market penetration and ramp-up to be slow moving forward.”